Chemotherapy and endocrine function in lung cancer.

Area of Science:

• Endocrinology
• Oncology
• Pharmacology

Background:

• Chemotherapy is a cornerstone treatment for lung cancer.
• The impact of cyclic chemotherapy on endocrine function in male patients requires further investigation.
• Monitoring hormonal changes is crucial for managing potential side effects.

Purpose of the Study:

• To assess the influence of cyclic chemotherapy on endocrine function in male lung cancer patients.
• To evaluate changes in key hormones including thyroxine, cortisol, testosterone, SHBG, estradiol, FSH, LH, and transcortin.
• To identify potential endocrine gonadal dysfunction induced by chemotherapy.

Main Methods:

• Prospective monitoring of 12 male lung cancer patients undergoing cyclic chemotherapy.
• Hormonal assays (thyroxine, cortisol, testosterone, SHBG, estradiol, FSH, LH, transcortin) conducted every three weeks.
• Two common chemotherapy regimens were administered: cisplatin/etoposide and vincristine/doxorubicin/cyclophosphamide.

Main Results:

• Significant elevations in sex hormone binding globulin (SHBG) and follicle-stimulating hormone (FSH) levels were observed after 6-9 weeks of therapy.
• No significant changes were noted in thyroxine, cortisol, testosterone, estradiol, LH, or transcortin levels.
• Increased SHBG levels suggest a potential decrease in free testosterone and altered androgen/estrogen ratios.

Conclusions:

• Cyclic chemotherapy for lung cancer can induce endocrine gonadal dysfunction in male patients.
• Elevated SHBG and FSH levels are key indicators of this dysfunction.
• The underlying mechanisms for increased SHBG require further research.